Globoid Cell Leukodystrophy (Krabbe Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Globoid Cell Leukodystrophy (Krabbe Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Krabbe disease, also called globoid cell leukodystrophy, is a degenerative disorder caused by a deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, muscle spasms, loss of head control, vomiting, fever, irritability, and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsants, muscle relaxers) and providing supportive care.
The Globoid Cell Leukodystrophy (Krabbe Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Globoid Cell Leukodystrophy (Krabbe Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Globoid Cell Leukodystrophy (Krabbe Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Globoid Cell Leukodystrophy (Krabbe Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Globoid Cell Leukodystrophy (Krabbe Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Apteeus SASBial - Portela & Ca SA
BioStrategies LC
BioXcel Corp
Duke University
Forge Biologics Inc
Gain Therapeutics Inc
M6P Therapeutics
Neuway Pharma GmbH
Polaryx Therapeutics Inc
San Raffaele Scientific Institute
Vascumab LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Globoid Cell Leukodystrophy (Krabbe Disease) reports